LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akciju saraksts・Lisata Therapeutics

L
Lisata Therapeutics

Atvērts

4.57 0.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.5600000000000005

Max

4.58

Galvenie mērījumi
By Trading Economics
Darbinieki	26

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 26. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	14M 34M
Iepriekšējā atvēršanas cena	4.35
Iepriekšējā slēgšanas cena	4.57

Lisata Therapeutics Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. febr. 23:21 UTC

Iegādes, apvienošanās, pārņemšana

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

2026. g. 15. febr. 23:45 UTC

Tirgus saruna

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

2026. g. 15. febr. 23:40 UTC

Tirgus saruna

Gold Falls on Possible Position Adjustments -- Market Talk

2026. g. 15. febr. 23:06 UTC

Peļņas

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

2026. g. 15. febr. 23:04 UTC

Peļņas

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

2026. g. 15. febr. 23:04 UTC

Peļņas

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

2026. g. 15. febr. 23:01 UTC

Peļņas

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

2026. g. 15. febr. 23:01 UTC

Peļņas

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

2026. g. 15. febr. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

2026. g. 15. febr. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

2026. g. 15. febr. 22:52 UTC

Iegādes, apvienošanās, pārņemšana

Qube Shareholders to Receive A$5.20/Share in Cash

2026. g. 15. febr. 22:52 UTC

Iegādes, apvienošanās, pārņemšana

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

2026. g. 15. febr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope CEO Tania Archibald Speaking on a Call With Media

2026. g. 15. febr. 22:17 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

2026. g. 15. febr. 22:16 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

2026. g. 15. febr. 22:14 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

2026. g. 15. febr. 22:14 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

2026. g. 15. febr. 20:48 UTC

Peļņas

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

2026. g. 15. febr. 20:47 UTC

Peļņas

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

2026. g. 15. febr. 20:46 UTC

Peļņas

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

2026. g. 15. febr. 20:45 UTC

Peļņas

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

2026. g. 15. febr. 20:44 UTC

Peļņas

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

2026. g. 15. febr. 20:44 UTC

Peļņas

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

2026. g. 15. febr. 20:43 UTC

Peļņas

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

2026. g. 15. febr. 20:42 UTC

Peļņas

BlueScope Net Debt A$2.2 Million at Dec. 31

2026. g. 15. febr. 20:42 UTC

Peļņas

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

2026. g. 15. febr. 20:41 UTC

Peļņas

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

2026. g. 15. febr. 20:40 UTC

Peļņas

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

2026. g. 15. febr. 20:40 UTC

Peļņas

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

2026. g. 15. febr. 20:39 UTC

Peļņas

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Salīdzinājums

Cenas izmaiņa

Lisata Therapeutics Prognoze

Vērtējuma vienprātība

By TipRanks

Neitrāls

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Lisata Therapeutics — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Par Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.